Al-Rawi TSS, Al-Ani RM. Liver dysfunction-related COVID-19: A narrative review. World J Meta-Anal 2023; 11(1): 5-17 [DOI: 10.13105/wjma.v11.i1.5]
Corresponding Author of This Article
Raid M Al-Ani, MBChB, Academic Research, Full Professor, Senior Editor, Surgeon, Department of Surgery/Otolaryngology, University of Anbar College of Medicine, Al-Thaela, Ramadi City 31001, Anbar, Iraq. med.raed.alani2003@uoanbar.edu.iq
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Meta-Anal. Jan 12, 2023; 11(1): 5-17 Published online Jan 12, 2023. doi: 10.13105/wjma.v11.i1.5
Liver dysfunction-related COVID-19: A narrative review
Taghreed S Saeed Al-Rawi, Raid M Al-Ani
Taghreed S Saeed Al-Rawi, Department of Biochemistry, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq
Raid M Al-Ani, Department of Surgery/Otolaryngology, University of Anbar College of Medicine, Ramadi City 31001, Anbar, Iraq
Author contributions: Al-Ani RM designed the study, wrote the abstract, core tip, introduction, and conclusion, formatted the references, edited the draft, and prepared the final version of the manuscript; Al-Rawi TSS collected the references and wrote the majority of the manuscript; both authors revised and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors declare that there is no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Raid M Al-Ani, MBChB, Academic Research, Full Professor, Senior Editor, Surgeon, Department of Surgery/Otolaryngology, University of Anbar College of Medicine, Al-Thaela, Ramadi City 31001, Anbar, Iraq. med.raed.alani2003@uoanbar.edu.iq
Received: September 9, 2022 Peer-review started: September 9, 2022 First decision: November 17, 2022 Revised: November 25, 2022 Accepted: December 13, 2022 Article in press: December 13, 2022 Published online: January 12, 2023 Processing time: 123 Days and 21.5 Hours
Core Tip
Core Tip: There is a diversity of clinical manifestations of the coronavirus 2019 disease (COVID-19), ranging from classical presentations like fever, cough, and dyspnea to non-classical presentations like liver involvement. Direct injury, drug-induced hypoxia, abnormal liver function tests, cytokine storm, and a history of chronic hepatic diseases are the proposed mechanisms of liver involvement during the COVID-19 course. Liver involvement can determine the severity of the disease. Old age and a history of chronic diseases like diabetes mellitus are recognized risk factors for this involvement. Autoimmune hepatitis is an example of liver involvement following COVID-19 vaccination. However, complete vaccination with 3rd and 4th booster doses is required in patients with chronic liver diseases. We aim to summarize the various aspects of hepatic involvement during the COVID-19 course or following its vaccination.
